PT-141
Also known as: Bremelanotide, Vyleesi
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A melanocortin receptor agonist that acts on the nervous system rather than the vascular system; one formulation (bremelanotide / Vyleesi) is FDA-approved for a specific indication.
What it is & how it works
What it is
PT-141, known generically as bremelanotide, is a melanocortin receptor agonist. Unlike vascular-acting drugs, it works centrally — on the nervous system. One formulation is FDA-approved under the brand Vyleesi for a specific indication.
How it works
By activating melanocortin receptors (notably MC4R) in the central nervous system, bremelanotide influences sexual-desire pathways. This central mechanism is what distinguishes it from blood-flow-based approaches.
Evidence and the approval line
There is approval-grade human evidence for the specific, narrow indication the product is cleared for. Community use beyond that indication — and use of unapproved gray-market PT-141 — does not carry the same evidence or the label-based safety screening, so the two should not be conflated.
What it's discussed & studied for
- Libido and sexual function (approved use exists for a narrow indication)
Discussion of a use is not a claim that it works or is approved.
Research status
The bremelanotide formulation (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women; broader community use is off-label/unapproved.
Evidence quality
Mixed by use. There is approval-grade human evidence for the specific indication; community use beyond that is not similarly validated.
Dosing discussion
The approved product has a defined label and route. Gray-market PT-141 used outside that context is not following validated guidance.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Reported effects include nausea, flushing, and transient blood-pressure changes; the approved label details contraindications. Use of unapproved product bypasses those safeguards.
Sourcing literacy
An FDA-approved version exists; unregulated 'PT-141' carries the usual identity/purity/sterility risks and skips label-based safety screening.
Selected literature
FAQ
Is PT-141 approved?
The bremelanotide formulation (Vyleesi) is FDA-approved for a specific, narrow indication. Use outside that is off-label or via unapproved product.
How is its mechanism different from ED drugs?
It acts on melanocortin receptors in the nervous system rather than on blood vessels, so its mechanism is centrally mediated rather than vascular.